Mineralys Therapeutics reported a third-quarter loss of $0.64 per share, missing the consensus estimate of a $0.53 loss by 20.8%. Earnings fell 23.1% from a year earlier, when the company lost $0.52 per share. As a pre-revenue company with no sales, the miss matters less as a profitability signal than as a measure of how quickly launch costs are building. The central tension is that Mineralys is better prepared to commercialize lorundrostat than it was three months ago, ahead of a December 22, 2026 PDUFA date. Over the same stretch, investors have grown far less willing to pay for that readiness. The stock fell into the report at a 52-week low.

The composition of the loss explains the miss. Net loss widened to $57.3 million from $36.9 million. Research and development spending fell to $22.7 million from $31.5 million as the pivotal program wound down. That relief was swamped by general and administrative expense, which nearly quadrupled to $37.4 million from $9.7 million. The increase was driven by $15.4 million in higher professional fees and $11.4 million in personnel costs tied to commercial build-out. The sequential path is steeper still: G&A ran $21.0 million in the first quarter, $24.7 million in the second and $37.4 million in the third. The June term loan added $3.2 million of interest expense, up from $0.8 million in the second quarter, which cut total other income to $2.8 million. Weighted shares rose to roughly 89.0 million from 70.6 million a year ago, so per-share losses also carry the weight of prior financing.

Operationally, the call showed clear progress. In the second quarter only sales leadership was in place. The full field force is now hired, with reps averaging about 15 years of industry tenure. Payer discussions have been completed with the vast majority of payers, and a full-service patient support program is being finalized. The clinical package also improved:

• A new Launch-HTN analysis showed 46% of patients on the 50 mg dose reached the guideline systolic target of below 130 mmHg at Week 12.
• More than two-thirds of those patients achieved a reduction of at least 10 mmHg.
• Blood-pressure effects were consistent across CKD stages 1-3, and albuminuria fell 52% versus placebo.
• Late-breaking long-term Transform-HTN data are scheduled for AHA.

Management's tone toward the competitive landscape also shifted. After describing it as "too early" on earlier calls, the company now cites AstraZeneca's baxdrostat as class validation, pointing to about $9 million in first-full-quarter revenue and roughly 12,000 new patient starts.

That same comparison, however, gives bears legitimate ammunition. Baxdrostat's early figures imply a low net price and heavy buy-downs, which raises gross-to-net uncertainty for a second entrant. Mineralys again acknowledged it will miss the Medicare Part D bid cycle. AstraZeneca's own expectation of full Medicare coverage only by 2028 suggests lorundrostat will depend on the exceptions process in a hypertension market heavily weighted toward Medicare. Other overhangs include:

• Potential baxdrostat primary-aldosteronism data next year.
• GLP-1 hypertension readouts in obese patients.
• Final Explore-OSA results that again showed no apnea-hypopnea benefit, despite a solid 11.1 mmHg blood-pressure reduction.
• Management's refusal to give pricing, launch metrics or a next development indication.
• Partnering that remains under evaluation, with no deal announced.

The balance sheet buys time but not unlimited time. Cash and investments stood at $624.7 million, down from $661.4 million at the end of the second quarter, alongside a roughly $98 million term loan. Runway guidance into 2028, including launch, was unchanged. Spending will likely keep rising once launch begins, however, so that runway hinges on how quickly prescriptions and net revenue build.

The market has been treating this setup harshly. Shares have dropped 36.3% since the open following the August report, to $15.99. That leaves the stock 40.5% below its 200-day moving average of $26.86 and half its September 9 inter-earnings high of $31.99. It also sits just 4.3% above the $15.33 low set on November 3, the day before the release. Investor sentiment, measured before the report, moved from essentially neutral (0.0004) to clearly negative (-0.26). That is a meaningful deterioration in expectations, not a marginal one. The Earnings Whispers trend signals are mostly negative, with price, sequential growth and AVWAP all pointing lower.

The bottom line is that Mineralys executed on what it controls, including the sales force, payer groundwork and supporting data, while the EPS miss reflects deliberate launch spending rather than operational slippage. Investors' concern has shifted from whether lorundrostat works to whether it can be priced, reimbursed and differentiated profitably behind baxdrostat. With no pricing, Medicare clarity or launch metrics offered, the December PDUFA decision and early access terms now carry most of the burden of resetting a deeply skeptical setup.